CompaniesNervGen Pharma

NervGen Pharma

active

Vancouver, BC, Canada

Founded 2017

About

Peptide inhibitor of protein tyrosine phosphatase sigma

Areas of Focus

Categories

Gene Therapy, RNA & Peptide Therapy

Team (15)

Adam Rogers, MD

Brian McAlister

Brian McAlister

View all 15 team members →

Clinical Trials (2)

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

114

By Phase

PHASE1/PHASE2: 1PHASE1: 1

By Status

RECRUITING: 1COMPLETED: 1

Clinical Trials Pipeline2 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2020

2021

2022

2023

2024

2025

2026

2027

Today

Hover over trial bars to see details

Recent Trials

NCT05965700Lead Sponsor

NVG-291 in Spinal Cord Injury Subjects

PHASE1/PHASE2Recruiting

40 participants

Started: Aug 8, 2023 · Completed: Apr 30, 2026

NCT05308953Lead Sponsor

A Phase I Safety Study of NVG-291 in Healthy Adults

PHASE1Completed

74 participants

Started: May 6, 2021 · Completed: Jul 3, 2023

Funding History (9)

D

Dec 14, 2021

D/A

Aug 25, 2021

D

Aug 17, 2021

D/A

Jun 2, 2021

D

Aug 25, 2020

D

Jun 3, 2020

D

Nov 22, 2019

D

Mar 21, 2019

D

Sep 20, 2018

Locations (1)

Headquarters

Vancouver, BC, Canada

Map

Loading map...